The previously reported data on the existence of herpes simplex-genitalis virus nonvirion; neoantigens with distinctive properties, and on the presence of specific antibodies for these neoantigens only in the sera of specially hyperimmunized guinea pigs or The purpose of this communication is to record the failure to reproduce the data, contained in three reports to these PROCEEDINGS (1-3), and to describe the tests that are the basis for negating the conclusions. The earlier reports (1-3) and subsequent unpublished work in 1973 were the basis for the following important conclusions:
The purpose of this communication is to record the failure to reproduce the data, contained in three reports to these PROCEEDINGS (1) (2) (3) , and to describe the tests that are the basis for negating the conclusions. The earlier reports (1) (2) (3) and subsequent unpublished work in 1973 were the basis for the following important conclusions:
1. Specific, labile, nonvirion (NV) neoantigens are formed in guinea pig kidney (GPK), young rabbit kidney (YRK), and tissue culture cells obtained from a human cell line derived from epidermoid carcinoma of the larynx (HEp2) infected with a high multiplicity of virus (20 or more plaque-forming units per cell) of herpes simplex (labialis) virus, subtype 1 (HSV 1) and herpes simplex (genitalis) virus, subtype 2 (HSV 2) . No method was found for separating these antigens from adsorbed virus or from newly synthesized structural, viral antigens. The instability of these "NV" antigens at low temperatures when contrasted with the stability of viral, structural complement fixing (CF) antigens, especially at 40, made it possible to obtain CF virion (V) antigens without the "NV" antigens, and to use the antigens, stored at 40 for an appropriate time, for the absorption of the CF as well as the neutralizing antibodies for these viruses (1, 2) .
Abbreviations: HSV 1, herpes simplex (labialis) virus, subtype 1; HSV 2, herpes simplex (genitalis) virus, subtype 2; GPK, guinea pig kidney; YRK, young rabbit kidney; HEp2, a human cell line derived from an epidermoid carcinoma of the larynx; C', complement; CF, complement fixing; AC', anticomplementary; V, virion; NV, nonvirion. *Reprint requests should be sent to Dr. Sabin, Expert Consultant, National Cancer Institute, National Institutes of Health, Building 31, Room 2B43, Bethesda, Md. 20014. 2. Highly specific CF antibodies for these "NV" neoantigens are produced (a) by hyperimmunizing guinea pigs with GPK cultures that had been grown in guinea-pig serum and had been harvested 3 hr after infection with a high multiplicity of either of these viruses, that had been serially passaged in GPK cultures grown in guinea-pig serum, and (b) absorbing antibodies to V antigens from the antisera. The sera from guinea pigs, hyperimmunized with nine different HSV 1 strains, were reported (2) to react only with "NV" antigens produced by HSV 1 strains, but not with comparable antigens prepared with HSV 2 strains, even though the HSV 2 strains produced high concentrations of CF-V antigens which reacted with a broad spectrum HSV 1 rabbit antiserum. On the other hand, the serum from a single guinea pig hyperimmunized with the HSV 2, "Justin" strain was reported to react in comparable titers with "NV" antigens produced not only by several HSV 2 strains but also by HSV 1 strains (2). However, the serum from another guinea pig hyperimmunized with the "Curtis E304" strain of HSV 2 was reported to react only with "NV'' antigens produced by HSV 2 strains (including the "Justin" strain) but not with HSV 1 "NV" antigens, although this "Curtis E304" strain also produced high-titered CF antibodies for HSV 1, V antigens (unpublished data).
3. Humans (after primary or recurrent infections with these viruses) and experimental animals (after single infections and hyperimmunization with highly infectious virus preserved at low temperatures for weeks or months) had no CF antibodies for these "NV" antigens when their sera were absorbed with properly stored, 40-stable, V antigens. 4 . The procedure for testing human sera against HSV 1 and HSV 2 "NV" antigens, consisted, first, of absorption of the CF-V antibodies with a mixture of HSV 1 (3), in addition to the usual "NV" antigen and antibody monitoring tests with the absorbed HSV 1 and HSV 2 guinea-pig sera. The extraordinary specificity of the positive results for the 14 varieties of invasive human cancer (Table 2) , all of which were obtained in 1973 in coded tests that always included negative sera, plus the various control tests previously reported (3), led to the conclusion that an etiologic association existed between these viruses and these cancers. Moreover, the absence of these antibodies in the sera of many patients during the earliest stages of carcinoma (carcinoma in situ), as well as in the sera of 57 patients with 4-5 year "cures" ( 
FACTORS OF METHODOLOGY
The materials and procedures used (originally) were those described earlier (1, 2) with the special precautions mentioned in the last publication (3) . However, as test after test in which variables such as medium, serum, tissue culture bottles, l)assage level, and source of virus stocks, etc. for the production of "NV" antigens, as well as the reagents used in the CF tests, yielded negative results, it became apparent that the precision with which the various methods were used was of great significance. Although the importance of using neither too much nor too little "free" C' for detection of both V and "NV" antigens of experimentally oncogenic DNA viruses was previously recognized (4) (5) (6) (7) (8) (9) and was the basis for adopting 1.5 exact units for our CF tests (1) (2) (3) , it became apparent during (1974) the course of the present studies that the amount of C' used was indeed crucial. For example, it was found that a guineapig serum that was considered to have had its V antibody completely absorbed whell C' dilutions of 1:8 or 1:10 were used, still had demonstrable V antibody with C' diluted 1:13 when a much less AC',V antigen was used. Thus, it became clear how important it was to control by carefully standardized methods the various factors that influenced the precision of measuring the C' and the AC' activity of the absorbed sera and of the HEp2 cell suspensions that were the source of V, CF antigen. The stable reagents of the CF test are the C' and the hemolysin, whereas the sheep erythrocytes are variable; the duration of their storage in Alsever's solution and as washed suspensions at 4" influences the amount of C' required. Extensive tests in 1974 showed that when equal parts of sheep blood and Alsever's solution are stored at 40 for less than 8-9 days after bleeding, and are then used on the day of washing or the following day, there are great irregularities in the titration of hemolysin; these irregularities can decrease the sensitivity of C' detection and thus contribute to false positive and negative results in a system that is dependent on having 1.5 exact units of C' in an antigen-antibody mixture. It was also noted that different lots of hemolysin could give different values for one unit of the same C' when tested with the same erythrocytes.
Problems of AC' Activity of antigens and Absorbed Sera. The washed GPK cell suspensions from which the "NV" antigens (always mixed with some V) are prepared, as a rule, have little or no AC' activity, i.e., C'-binding per se, and also no C'-enhancing activity. The HEp2 cell suspensions, however, from which the 40 stored, V antigens are prepared are often very anticomplementary. Considerable variation was encountered during the present studies among different HEp2 preparations, i.e., from 0.12 ml to 0.24 ml of a 1:25 dilution of the same C' and hemolysin combination which, with the sheep erythrocytes used, regularly required only 0.06 ml or 0.04 ml in Ca-Mg saline for one hemolytic unit in titrations performed at 0.01-ml intervals.
The procedure for removing the CF, V antibodies from the human sera and for monitoring guinea-pig sera before they were tested for "NV" antibodies, included a final step of centrifugation at 37,000 rpm (Spinco no. 40 rotor) for 2 hr so that as much of the C'-binding antigen-antibody complexes (1-3) were removed as was possible. It was realized from the beginning that it was necessary to avoid drawing off the fluid at the very bottom near the solidly packed pellet of insouble material. However, because the quantities of human and guinea-pig sera were usually too small to yield the volume needed for a complete CF test, the hundreds of specimens routinely prepared varied considerably in their anrticomplementary activity. Some of the absorbed sera were as anticomplementary as the most anticomplementary HEp2 virion preparations, whereas others were in the wide range in between. In a complete CF test on any absorbed serum with both GPK and and HEp2 antigens, the amount of C' used in any mixture was determined by the C' requirements of the most anticomplementary component. For example, if for 1.5 exact units of C' the absorbed serum required the addition of 0.1 ml of C' di- Appreciation of the need for very careful measurement of the AC' activity of absorbed sera led to a number of tests with larger volumes of serum. When larger volumes of absorbed serum were used for the final centrifugation at 37,000 rpm, a marked difference was found in the AC' activity of the upper two-thirds of the supernatant, e.g., 0.09 ml of C' diluted 1:25 for one hemolytic unit as compared to 0.14 ml for the lower third even though the small amount of fluid at the bottom was left behind. This difference meant that for the 1.5 units, C' diluted 1:18.5 was indicated if the upper two-thirds were used as compared to a dilution of 1:12 if the lower third was used.
Another unexpected finding was that some hemolysins can by themselves lower the AC' activity of HEp2 antigens. When the reagents used in another laboratory were compared with those used at the Frederick laboratory, it was found that one lot of hemolysin hemagglutinated sheep erythrocytes whereas another hemolysin did not, in approximately similar dilutions. The C' titer in Ca-Mg saline was the same for both hemolysins with some lots of erythrocytes but not with others; in either case, the hemagglutinating hemolysin reduced the C' requirement for one hemolytic unit of different HEp2 antigens from 0.14 ml to 0.11 ml, from 0.12 ml to 0.08 ml, and from 0.23 to 0.16 ml of the 1 :25 dilution.
SUMMARY OF TESTS
All guinea-pig sera used for monitoring the "NV" antigens, and 40-stored HEp2 cell, V antigens had been used up by tions from uninfected aliquots of the GPK cells (grown in guinea-pig serum) that were used for infection with either HSV 1 ("Schooler" strain) for use in 10 guinea pigs or HSV 2 (the "Curtis E304" strain) for use in 10 guinea pigs. The latter HSV 2 strain was previously used for the production of a single guinea-pig serum, no. 107, which was reported as having "NV" antibody only for HSV 2 strains which included the "Justin" strain used in all previous work (1-3) ; this guineapig 107 serum was the HSV 2 monitoring serum used in all the tests at the Frederick laboratory during the latter part of 1973. The guinea pigs received five doses, each smaller than the recommended amount (1) , from November 14 to December 6, 1973 and a sixth dose of only 0.5 ml (instead of 3 ml) of 10% GPK cell suspension 6 weeks later. The serum from each guinea pig was absorbed and tested separately to determine possible variations in the production of cross-reacting "NV" antibodies for both virus types (2) sera were found to be still reactive with our less anticomplementary, 40-stored HEp2 cell, V antigens as well as with the various GPK cell antigens when C' at the 1:13 dilution level for the 1.5 exact units for these sera was used as in the other laboratory; but when the C' level was raised to 1:10, the results became negative for both the HEp2 cell V antigens
